bluuebunny/crossref_metadata_2025_split huggingface dataset:
Rasburicase
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The January 2003 monograph topics are ezetimibe, enfurvitide, aripiprazole, atomoxetine, and amoxicillin/clavulanate potassium extended-release tablets. The DUE is on ezetimibe.
Use Metric Weight to Express Liquid Doses;Tuberculin Syringe Confused with Insulin Syringe;Duragesic Patch Abuse
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Gabapentin: Hyperhidrosis
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Prevent Mix-ups between Vaccines and Neuromuscular Blockers;Confusing Haemophilus b Conjugate Vaccine with Influenza Vaccine;Proliferation of Insulin Combination Products Increases Opportunity for Errors
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Acetylcysteine: Prevention of Contrast Media Nephropathy
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data-including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations-precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Stability of Imipenem-Cilastatin Sodium in AutoDose Infusion System Bags
Authors: Trissel Lawrence A. , Xu Quanyun A. 
Published: January 2018

The objective of this study was to evaluate the physical and chemical stability of imipenem-cilastatin sodium 250 mg/100 mL and 500 mg/100 mL (of each drug component) admixed in 0.9% sodium chloride injection packaged in AutoDose Infusion System bags. Triplicate test samples were prepared by bringing the required amount of imipenem-cilastatin sodium injection to volume with 0.9% sodium chloride injection. A total of 100 mL of each of the test solutions was packaged in each of three ethylene vinyl acetate (EVA) AutoDose bags designed for use in the AutoDose Infusion System for each storage condition. Samples were protected from light and evaluated at appropriate intervals for up to three days at 23°C and 14 days at 4°C. Physical stability was assessed using a multistep evaluation procedure that included turbidimetric and particulate measurement in addition to visual inspection. Chemical stability was assessed with stability-indicating high performance liquid chromatography (HPLC) analytical techniques, based on initial drug concentrations and concentrations at appropriate intervals over the study periods. The admixtures were clear throughout the study when viewed in normal fluorescent room light and with a Tyndall beam. Measured turbidity and particulate content were low initially and exhibited little change throughout the study. HPLC analysis revealed extensive decomposition in the samples, with imipenem being the less stable component. The instability of the imipenem-cilastatin sodium admixtures is consistent with previous studies. Admixtures stored under refrigeration should be used immediately upon warming to room temperature due to the rapid rate of imipenem decomposition. The AutoDose Infusion System bags were not found to affect adversely or improve the physical and chemical stability of this drug.
With Levothyroxine, Be Careful where you Put the Decimal; It Should Go without Saying: Successful Weight-Based Programs Require a Weight; Don't Confuse Varicella Virus Vaccine with Varicella-Zoster Immune Globulin
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Baclofen: Alcohol Withdrawal
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Icodextrin Peritoneal Dialysis Solution
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.
An Assessment of Free, Online Drug-Drug Interaction Screening Programs (DSPs)
Authors: Lam Minh V. , Mccart Gary M. , Tsourounis Candy 
Published: January 2018

Objective This study evaluated the content and usability of four free, online drug-drug interaction screening programs (DSPs) and one proprietary DSP (CD-ROM format) requiring an annual fee. Methods Free, online DSPs that obtain their drug interaction information from unique providers were located through a comprehensive search of the Internet. For comparison purposes, a well-established, fee-based DSP was also included in the study. A tool for evaluating the DSPs for usability and quality of content was created. The usability characteristics assessed included ease of use, ability to support more than two drug entries at the same time, speed, and multifunctionality. Evaluation of content was based on accuracy, completeness, references, drug interaction management, and readability. A five-member panel of clinical pharmacists and drug information specialists in academia and the pharmaceutical industry validated the survey tool. Results Based on overall usability, Drkoop.com (Multum) rated higher than the other free DSPs, but below the comparator, DrugReax (Micromedex). Walgreens.com (Medi-Span) and Medscape (First Data-Bank) ranked lowest among all the DSPs in terms of usability. Based on content, Walgreens ranked first and Clinical Pharmacology 2000 (Gold Standard Multimedia) ranked last (P= 0.015, ANOVA). Conclusion All of the evaluated DSPs were useful. Some were better than others depending on the assessment category. Walgreens rated the highest in terms of accuracy, completeness, and drug interaction management information. Drkoop.com rated the highest with regard to comprehensive references and pharmacist-assessed, consumer-friendly language. All of the free, online DSPs could improve their speed of information retrieval.
Will CDC-Recommended Vaccine Abbreviations Reduce the Risk of Misinterpretation? Unintended Discontinuation of Drugs a Patch or Oral Therapy? Oral Vancomycin Does Not Treat Systemic Infections
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Tracking Vaccination Rates among HIV-Positive Patients with a Computerized Reminder System
Authors: Segarra-Newnham Marisel 
Published: January 2018

Objective This study deterimined vaccination rates at a Veterans Affairs HIV clinic before and after the 1997 implementation of a computerized reminder system. Methods Before implementation of a computerized reminder system, vaccinations were not always recorded on patients' medical records. After implementation, vaccinations were documented in the computer record and the system alerted providers when patients became due for a pneumococcal vaccine, tetanus booster, or other immunization. Charts for all patients (n = 211) enrolled in the HIV clinic were assessed for vaccination dates. Vaccination rates for patients (n = 71) enrolled before 1997 were compared with rates for patients (n = 140) enrolled after the computerized system was installed. The new system enabled the clinical pharmacist to monitor vaccination rates on a quarterly basis and facilitate patient appointments. Results Vaccination rates for patients enrolled before 1997 were 100% for initial pneumococcal vaccination and 100% for tetanus. Seventy-six percent of patients due for a pneumococcal vaccine booster had received it. In contrast, patients enrolled after 1997 had vaccination rates of 94% for pneumococcal vaccine; eight recently enrolled patients did not have documentation of vaccination. The clinical pharmacist scheduled these patients and the rate increased to 97%. Due to a product shortage, only 61% of patients enrolled after 1997 had received tetanus vaccine. Conclusions A computerized reminder system allows for reliable tracking of vaccination rates and can be used by pharmacists to improve preventive care for HIV-positive patients. Overall vaccination rates were well above the national norm.
Zoledronic Acid: Postmenopausal Osteoporosis
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Low-Molecular-Weight Heparin Therapy for Patients Undergoing Total Knee Replacement Surgery: Cost and Outcomes
Authors: Allen Lisa R. , Bonck Michael J. , Lofgren Kendra L. , Mayo Kevin W. , Mozaffari Essy 
Published: January 2018

Objective: In March 1997, a community hospital system changed the low-molecular-weight heparin (LMWH) product on formulary from enoxaparin to dalteparin through a therapeutic interchange for all uses except patients undergoing total knee replacement (TKR) surgery. In October 1997, therapeutic interchange of LMWHs (enoxaparin to dalteparin) was instituted for patients undergoing TKR surgery. The cost equivalence of these therapies in TKR surgery was evaluated. Methods: A cohort of patients admitted to three health-system facilities who underwent primary TKR surgery between July 1, 1996 and December 31, 1998 was assembled retrospectively. Costs and outcomes associated with a formulary interchange for LMWH products (from enoxaparin to dalteparin) initiated in October 1997 for TKR surgery were analyzed using data abstracted hospital records and decision support systems. To evaluate equivalence between the drugs, the difference in median inpatient health care costs (with 95% confidence intervals [CIs]) was calculated. Equivalence of outcomes (eg, adverse events) in terms of risk ratios was also evaluated. Results: Inpatient costs were essentially equivalent for patients treated with enoxaparin (n = 88) and dalteparin (n = 101), with a slightly higher median cost among enoxaparin-treated patients ($172 [95% CI, -$17 to + $395]). CIs for the crude and regression-adjusted findings included the possibility of no cost difference (ie, $0). The median time to hospital discharge was identical, at 6 days. Outcomes were otherwise similar between the two groups. Conclusions: Our therapeutic interchange program was successful. Inpatient costs were equivalent when patients were treated with either enoxaparin or dalteparin for TKR surgery.
Factors Affecting Job Satisfaction among Hospital Pharmacists
Authors: Sansgiry Sujit S. , Ngo Caroline 
Published: January 2018

Objective Job satisfaction is the favorableness with which employees view their work. Two main factors that affect job satisfaction are intrinsic and extrinsic job characteristics. Intrinsic factors lead to satisfaction, whereas extrinsic characteristics prevent dissatisfaction. The objective of this study was to determine the level of job satisfaction among hospital pharmacists at the Texas Medical Center by looking specifically at intrinsic and extrinsic factors that managers may use to promote a higher level of job satisfaction. Methods A survey about intrinsic and extrinsic job characteristics was administered to hospital pharmacists. The survey employed a 5-point “strongly agree” (5) to “strongly disagree” (1) scale; satisfaction was measured using two previously validated scales abbreviated as JS1 and JS2. Eighty-five completed surveys were received for a response rate of 26%. Results The mean age of the respondents was 40 years (± 9.7); the majority of respondents were female (64.3%). In general, pharmacists were satisfied with their job. The mean job satisfaction scores on the two scales were 3.32 ± 0.86 for JS1 and 3.43 ± 0.84 for JS2. Job satisfaction was significantly correlated with intrinsic (rJS1 = 0.61, rJS2 = 0.54, P < 0.05) and extrinsic factors (rJS1 = 0.64, rJS1 = 0.61, P < 0.05). Furthermore, intrinsic and extrinsic factors were significantly correlated with each other (r = 0.48, P < 0.05). Conclusion Hospital pharmacists at the Texas Medical Center were satisfied with their current jobs and liked their jobs. Intrinsic and extrinsic factors were significantly correlated with job satisfaction and with each other, indicating their importance when measuring job satisfaction.
Don't Lose Track of Orders during Clarification Never Prescribe Leucovorin Calcium as “Folinic Acid” Confusion Mounting over Drug Name Suffixes Fellowship in Medication Safety
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Don't Accept Verbal Chemotherapy Orders Zostrix Cream Confused with Zovirax Cream Know Each Drug's Purpose Verify Medication Histories Oral Morphine Alert
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.